2025国家医保谈判启动 引入“商保创新药目录”机制

Core Insights - The introduction of the "Commercial Insurance Innovative Drug Directory" mechanism marks a significant change in the healthcare policy, allowing for the inclusion of innovative drugs that are not yet part of the basic medical insurance directory but have high clinical value and patient benefits [1] Group 1 - The 2025 basic drug directory adjustment has 535 drug names passing the formal review [2] - The Commercial Insurance Innovative Drug Directory has 121 drug names passing the formal review, with 79 of them also applying for both the basic medical insurance directory and the commercial insurance innovative drug directory [2]